Improving Clinical, Cognitive, and Psychosocial Dysfunctions in Patients with Schizophrenia: A Neurofeedback Randomized Control Trial
Objectives. The aim of this study was to use neurofeedback (NF) training as the add-on therapy in patients with schizophrenia to improve their clinical, cognitive, and psychosocial condition. The study, thanks to the monitoring of various conditions, quantitative electroencephalogram (QEEG) and brai...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2021-01-01
|
Series: | Neural Plasticity |
Online Access: | http://dx.doi.org/10.1155/2021/4488664 |
id |
doaj-79ba68dea76c4d7eb6c3ea482390aa3e |
---|---|
record_format |
Article |
spelling |
doaj-79ba68dea76c4d7eb6c3ea482390aa3e2021-08-23T01:32:24ZengHindawi LimitedNeural Plasticity1687-54432021-01-01202110.1155/2021/4488664Improving Clinical, Cognitive, and Psychosocial Dysfunctions in Patients with Schizophrenia: A Neurofeedback Randomized Control TrialRenata Markiewicz0Agnieszka Markiewicz-Gospodarek1Beata Dobrowolska2Bartosz Łoza3Psychiatric Nursing DepartmentDepartment of Human AnatomyDepartment of Management in NursingDepartment of PsychiatryObjectives. The aim of this study was to use neurofeedback (NF) training as the add-on therapy in patients with schizophrenia to improve their clinical, cognitive, and psychosocial condition. The study, thanks to the monitoring of various conditions, quantitative electroencephalogram (QEEG) and brain-derived neurotrophic factor (BDNF), was supposed to give an insight into mechanisms underlying NF training results. Methods. Forty-four male patients with schizophrenia, currently in a stable, incomplete remission, were recruited into two, 3-month rehabilitation programs, with standard rehabilitation as a control group (R) or with add-on NF training (NF). Pre- and posttherapy primary outcomes were compared: clinical (Positive and Negative Syndrome Scale (PANSS)), cognitive (Color Trails Test (CTT), d2 test), psychosocial functioning (General Self-Efficacy Scale (GSES), Beck Cognitive Insight Scale (BCIS), and Acceptance of Illness Scale (AIS)), quantitative electroencephalogram (QEEG), auditory event-related potentials (ERPs), and serum level of BDNF. Results. Both groups R and NF improved significantly in clinical ratings (Positive and Negative Syndrome Scale (PANSS)). In-between analyses unveiled some advantages of add-on NF therapy over standard rehabilitation. GSES scores improved significantly, giving the NF group of patients greater ability to cope with stressful or difficult social demands. Also, the serum-level BDNF increased significantly more in the NF group. Post hoc analyses indicated the possibility of creating a separate PANSS subsyndrome, specifically related to cognitive, psychosocial, and BDNF effects of NF therapy. Conclusions. Neurofeedback can be effectively used as the add-on therapy in schizophrenia rehabilitation programs. The method requires further research regarding its clinical specificity and understanding mechanisms of action.http://dx.doi.org/10.1155/2021/4488664 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Renata Markiewicz Agnieszka Markiewicz-Gospodarek Beata Dobrowolska Bartosz Łoza |
spellingShingle |
Renata Markiewicz Agnieszka Markiewicz-Gospodarek Beata Dobrowolska Bartosz Łoza Improving Clinical, Cognitive, and Psychosocial Dysfunctions in Patients with Schizophrenia: A Neurofeedback Randomized Control Trial Neural Plasticity |
author_facet |
Renata Markiewicz Agnieszka Markiewicz-Gospodarek Beata Dobrowolska Bartosz Łoza |
author_sort |
Renata Markiewicz |
title |
Improving Clinical, Cognitive, and Psychosocial Dysfunctions in Patients with Schizophrenia: A Neurofeedback Randomized Control Trial |
title_short |
Improving Clinical, Cognitive, and Psychosocial Dysfunctions in Patients with Schizophrenia: A Neurofeedback Randomized Control Trial |
title_full |
Improving Clinical, Cognitive, and Psychosocial Dysfunctions in Patients with Schizophrenia: A Neurofeedback Randomized Control Trial |
title_fullStr |
Improving Clinical, Cognitive, and Psychosocial Dysfunctions in Patients with Schizophrenia: A Neurofeedback Randomized Control Trial |
title_full_unstemmed |
Improving Clinical, Cognitive, and Psychosocial Dysfunctions in Patients with Schizophrenia: A Neurofeedback Randomized Control Trial |
title_sort |
improving clinical, cognitive, and psychosocial dysfunctions in patients with schizophrenia: a neurofeedback randomized control trial |
publisher |
Hindawi Limited |
series |
Neural Plasticity |
issn |
1687-5443 |
publishDate |
2021-01-01 |
description |
Objectives. The aim of this study was to use neurofeedback (NF) training as the add-on therapy in patients with schizophrenia to improve their clinical, cognitive, and psychosocial condition. The study, thanks to the monitoring of various conditions, quantitative electroencephalogram (QEEG) and brain-derived neurotrophic factor (BDNF), was supposed to give an insight into mechanisms underlying NF training results. Methods. Forty-four male patients with schizophrenia, currently in a stable, incomplete remission, were recruited into two, 3-month rehabilitation programs, with standard rehabilitation as a control group (R) or with add-on NF training (NF). Pre- and posttherapy primary outcomes were compared: clinical (Positive and Negative Syndrome Scale (PANSS)), cognitive (Color Trails Test (CTT), d2 test), psychosocial functioning (General Self-Efficacy Scale (GSES), Beck Cognitive Insight Scale (BCIS), and Acceptance of Illness Scale (AIS)), quantitative electroencephalogram (QEEG), auditory event-related potentials (ERPs), and serum level of BDNF. Results. Both groups R and NF improved significantly in clinical ratings (Positive and Negative Syndrome Scale (PANSS)). In-between analyses unveiled some advantages of add-on NF therapy over standard rehabilitation. GSES scores improved significantly, giving the NF group of patients greater ability to cope with stressful or difficult social demands. Also, the serum-level BDNF increased significantly more in the NF group. Post hoc analyses indicated the possibility of creating a separate PANSS subsyndrome, specifically related to cognitive, psychosocial, and BDNF effects of NF therapy. Conclusions. Neurofeedback can be effectively used as the add-on therapy in schizophrenia rehabilitation programs. The method requires further research regarding its clinical specificity and understanding mechanisms of action. |
url |
http://dx.doi.org/10.1155/2021/4488664 |
work_keys_str_mv |
AT renatamarkiewicz improvingclinicalcognitiveandpsychosocialdysfunctionsinpatientswithschizophreniaaneurofeedbackrandomizedcontroltrial AT agnieszkamarkiewiczgospodarek improvingclinicalcognitiveandpsychosocialdysfunctionsinpatientswithschizophreniaaneurofeedbackrandomizedcontroltrial AT beatadobrowolska improvingclinicalcognitiveandpsychosocialdysfunctionsinpatientswithschizophreniaaneurofeedbackrandomizedcontroltrial AT bartoszłoza improvingclinicalcognitiveandpsychosocialdysfunctionsinpatientswithschizophreniaaneurofeedbackrandomizedcontroltrial |
_version_ |
1721199031185571840 |